Similarly, extensive data in preclinical cancer models [25–27] and in vitro cultures of patient samples [28] demonstrate that TIM-3 blockade enhances anti-tumour T cell responses, particularly in conjunction with PD-1 blockade. This evidence concerns the gene HAVCR2 and cancer.